Development and validation of patient-level prediction models for adverse outcomes following total knee arthroplasty

Ross D. Williams, MSc (1), Jenna M. Reps PhD (2), Peter R. Rijnbeek (1), Dani Prieto Alhambra PhD (3), Patrick B. Ryan PhD (2)

(1) Erasmus University Medical Centre, Rotterdam; (2)Janssen Research and Development, Raritan, NJ, USA ; (3) NDORMS, University of Oxford, Oxford, UK


Poster PDF

This activity under the European Health Data & Evidence Network (EHDEN) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union’s Horizon 2020 re-search and innovation programme and EFPIA. The sponsor of the study did not have any involvement in the writing of the manuscript or the decision to submit it for publication. The re-search was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). DPA is funded by a National Institute for Health Research Clinician Sci-entist award (CS-2013-13-012). TDS is funded by the Department of Health of the Generalitat de Catalunya under the Strategic Plan for Research and Innovation in Health (PERIS; SLT002/16/00308). The views expressed in this publication are those of the authors and not those of the NHS, the National Institute for Health Research or the Department of Health. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Competing Interests
JR and PBR are full-time employees of Janssen Research & Development, a pharmaceutical company of Johnson & Johnson, and shareholders in Johnson & Johnson. The Johnson & John-son family of companies also includes DePuy Synthes, which is the maker of medical devices for joint reconstruction.
DPA reports grants from Amgen, grants from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work.